Fresh Tracks Therapeutics, Inc.

Equities

FRTX

US10802T2042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:46:52 2024-05-28 pm EDT			5-day change	1st Jan Change
0.8601 ^USD	-4.45%		-6.51%	-2.16%

Mar. 15	Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index	CI

Brickell Biotech, Inc. Appoints Dr. Sanjeev Ahuja as Chief Medical Officer, with Effect from October 15, 2019

October 09, 2019 at 07:02 am EDT

On October 3, 2019, Brickell Biotech, Inc. entered into an employment agreement with Dr. Sanjeev Ahuja to serve as the Company’s Chief Medical Officer. Dr. Ahuja is expected to commence employment with the Company on October 15, 2019.

Latest news about Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index	Dec. 21	CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index	Dec. 18	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	23-09-20	MT
Top Premarket Gainers	23-09-20	MT
Fresh Tracks Therapeutics' Board Approves Liquidation Plan; Shares Rise After Hours	23-09-19	MT
Fresh Tracks Therapeutics, Inc. Announces Chief Executive Officer Changes	23-09-19	CI
Fresh Tracks Therapeutics, Inc. Announces Executive Changes	23-09-19	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately	23-07-25	CI
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note	23-07-21	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q1 Revenue $9,000	23-05-10	MT
Fresh Tracks Therapeutics, Inc. Announces Resignation of Gary A. Lyons from the Board of Directors	23-04-27	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q4 Revenue $2.1M	23-03-30	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
North American Morning Briefing : CPI Print Takes -3-	23-03-14	DJ
Investors Cautious Ahead of More Powell Testimony, Stifling US Equity Futures	23-03-08	MT
Top Premarket Gainers	23-03-08	MT
North American Morning Briefing : Stock Futures Struggle as More Powell Talk Looms	23-03-08	DJ
Fresh Tracks Therapeutics, Inc. Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02	23-03-07	CI

Chart Fresh Tracks Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FRESH TRACKS THERAPEUTICS, INC.	-2.16%	5.14M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.40%	21.83B
GENMAB A/S	-10.63%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs